Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The VDR–RAR shared nuclear signaling pathway represents the integrated transcriptional control exerted by the Vitamin D Receptor (VDR) and the Retinoic Acid Receptor (RAR). Both receptors are members of the nuclear hormone receptor superfamily and function as ligand-activated transcription factors that typically heterodimerize with the Retinoid X Receptor (RXR) to regulate gene expression [PMID: 1321494]. This shared signaling network is characterized by significant crosstalk, as VDR and RAR often compete for the limited intracellular pool of RXR and common co-regulators, which can lead to synergistic or antagonistic physiological effects depending on the cellular context [PMID: 7512024]. Biologically, this pathway is essential for maintaining calcium homeostasis, promoting cellular differentiation, and modulating immune responses, particularly within the skin and hematopoietic systems [PMID: 15556564]. Dysregulation of VDR–RAR signaling is implicated in various pathologies, including hyperproliferative skin disorders like psoriasis, metabolic bone diseases, and several malignancies such as acute promyelocytic leukemia [Source: NIH/StatPearls]. Pharmacological targeting involves the use of vitamin D analogs and retinoids, which are frequently utilized in clinical practice to treat dermatological conditions and certain cancers by inducing cell cycle arrest and differentiation [Source: PubChem]. However, therapeutic application is often limited by systemic safety concerns, most notably the risk of hypercalcemia associated with VDR activation and the potent teratogenic effects of RAR ligands [Source: FDA Labels].
Ligand-induced heterodimerization with Retinoid X Receptor (RXR) followed by binding to Vitamin D Response Elements (VDRE) or Retinoic Acid Response Elements (RARE) to modulate gene transcription.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vitamin D receptor and Retinoic acid receptor signaling pathway (VDR-RAR signaling) (VDR-RAR signaling).